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Abstract
Introduction: Steroid cell tumors of the ovary account for less than 0.1% of all ovarian tumors
[1] and these tumours may present at any age in association with interesting presentations related
to the hormonal activity and virilizing properties of tumor. Hayes and Scully [2] reported 63 cases
in patients ranging from 2 to 80 years of age. The subtype, not otherwise specified, is associated
with androgenic changes in approximately one half of patients with this tumour [1]. In a series of
63 cases from Massachusetts General Hospital, 94% of the tumors were found to be unilateral and
28.6% were malignant [3]. As most of these tumors are diagnosed at an early stage and do not recur
or metastasize, little is known about their response to therapies such as chemotherapy or radiation
[3].
Case Presentation: We present the case of a 22-year old lactating woman who presented with
four months of amenorrhea associated with signs of virilization. Clinical and diagnostic evaluation
revealed a right adenexal mass and elevated serum levels of testosterone and she was diagnosed as
having a stage 1A androgen secreting steroid cell tumor. In view of the early stage of the disease,
she underwent right salpingo-oopherectomy. Histopathological examination and
immunohistochemistry confirmed the diagnosis. Two months after surgery she regained normal
menses and showed regression of the androgenic changes.
Conclusion: Surgery remains the mainstay of the treatment of gonadotrophin receptor positive
steroid cell tumors although medical therapy using Gonadotrophin Releasing Hormone [GnRH
analogues has been tried recently in recurrent or inoperable cases. There is no described effective
chemotherapy or radiotherapy for this condition.
Introduction
Steroid cell tumors of the ovary account for less than 0.1%
of all ovarian tumors [1] and these tumors may present at
any age in association with interesting presentations
related to the hormonal activity and virilizing properties
of tumor. Hayes and Scully [2] reported 63 cases in
patients ranging from 2 to 80 years of age. The subtype,
not otherwise specified, is associated with androgenic
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changes in approximately one half of patients with this
tumor [1]. In a series of 63 cases from Massachusetts Gen-
eral Hospital, 94% of the tumors were found to be unilat-
eral and 28.6% were malignant [3]. As most of these
tumors are diagnosed at an early stage and do not recur or
metastasize, little is known about their response to thera-
pies such as chemotherapy or radiation [3].
Case presentation
This is the case of a 22-year-old uniparous lactating
woman who regained regular menses after 8 months of
lactational amenorrhea. After a period of six months of
regular menstruation she presented with a history of sud-
den onset of amenorrhea and abnormal hair growth on
the face of four months duration. Physical examination
revealed a male pattern of coarser hair distribution in the
beard region, anterior chest wall and arms. Abdominal
examination showed no abnormality and vaginal exami-
nation disclosed clitoromegaly. Ultrasonography of the
abdomen and pelvis revealed a solid right adenxal mass
measuring 51 × 54 × 58 mm with moderate to significant
vascularity. There was no ascites, retroperitoneal lym-
phadenopathy, adrenal gland enlargement, or liver metas-
tasis. Tumor markers and hormonal levels were evaluated
[Table 1] and showed raised serum testosterone levels.
The patient underwent an exploratory laparotomy. Intra-
operatively the right ovary showed a 5 × 5 cm firm, tan-
brown, well-encapsulated mass without any adhesions to
surrounding structures and with engorged ovarian vessels.
In view of the diagnosis of stage 1A disease, unilateral
right salpingo-oopherectomy alone was performed since
the frequency of lesions occurring bilaterally in this stage
has been reported to be only 6%.
The cut-section of the specimen showed a tan-brown well-
circumscribed tumor with areas of hemorrhage [Figure 1].
Microscopic examination [Figure 2] showed diffuse sheets
of large polygonal tumor cells with vacuolated cytoplasm
and vesicular nuclei along with nuclear pleomorphism.
Crystals of Reinke, which are usually seen in hilus tumors,
were not seen.
Immunohistochemistry staining was positive for gonado-
trophin receptors and vimentin, and negative for alpha-
fetoprotein and epithelial membrane antigen, providing
evidence in favour of a steroid cell tumor.
At post operative follow-up, two months of surgery, the
patient had regained normal menses. Her serum testoster-
one level had gone down to 0.262-ngm/ml, and there was
regression of the abnormal hair pattern. The patient is
being followed up regularly with measurement of hor-
mone levels as marker of recurrence.
Discussion
Ovarian steroid cell tumors account for less than 0.1% of
all ovarian tumors. They are grouped under sex-chord
stromal tumors and are usually benign, unilateral and
characterized by a steroid cell proliferation [1] &[3].
Histopathology Figure 2
Histopathology.
Table 1: Values of Hormone/tumor marker levels
Marker/Hormone Test value Normal values
CA-125 < 4 Units/ml 0–35 Units/ml
β-HCG 0.505 mIU/ml < 5 mIU/ml
S. Testosterone 309 ngm/ml 0.1–10 ngm/ml 
(In an adult female)
Alfa Fetoprotein 2.19 ngm/ml 0–15 ngm/ml
Cut section of the specimen Figure 1
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They are further divided into three subtypes: stromal leu-
teoma, Leydig cell tumor, and steroid cell tumor [1], [3]
&[4], the latter being the most common of the three sub-
types accounting for approximately 60% of cases.
Steroid cell tumors are associated with androgenic
changes with variable frequency, ranging from 12% to
over 50 % [1][4][5] &[6], and they are usually of many
years duration[1] &[3]. This case is unique because of its
acute presentation, with sudden onset of amenorrhea and
signs of virilization, over a four month period, following
resumption of menses after a normal delivery.
Historically these tumors have been variously referred to
as lipoid cell tumors, lipid cell tumors, adrenal-like
tumors, masculinovoblastomas, leutomas, hyperneph-
roid tumors, and adrenal rest tumors, indicating the infi-
delity of their supposed lineage [1], [2], [3][5]. However,
it is postulated that these are of adrenal cortical rest origin,
residing near the ovary, on the basis of the presence of
mRNA for steroidogenic p450c11 and p450c21, which are
expressed only in tissues of adrenal origin [7]. However
this theory is still disputed [1].
The majority of steroid cell tumors have a benign or low-
grade behavior. Interestingly, pathologically-benign
tumors can behave in a clinically malignant fashion [8].
About 20% patients develop metastatic lesions usually
within the peritoneal cavity, and rarely at distant sites [2]
&[9]. In a series of 63 cases from the Massachusetts Gen-
eral Hospital, 94% of the tumors were found to be unilat-
eral, and 28.6% cases had features suggestive of malignant
nature [2].
Hayes and Scully [2] have identified five pathologic fea-
tures that are highly associated with malignancy: More
than two mitoses per high-power field; necrosis; size of 7
cm or larger; hemorrhage; and Grade 2 or 3 nuclear atypia.
The final pathologic diagnosis is based on the characteris-
tic histological appearance, including polygonal to round
cells with distinct cell borders and an abundant cytoplasm
and the absence of Reinke's crystals, and a characteristic
pattern of immunohistochemistry staining for inhibin
and vimentin [75%], anti human cytokeratin [46%], and
AE1/AE3 [37%] [1].
The primary treatment is surgical extirpation of the pri-
mary lesion, and there are no reports of effective radiation
or chemotherapy [10]. In a young patient with stage IA
disease, a unilateral salpingo-oophorectomy is adequate
since the frequency of bilateral occurrence is only 6% (
[1], [2] &[10]).
The main reason for poor understanding of the therapeu-
tic value of chemotherapy and radiotherapy in the treat-
ment of these tumors is due to the rarity of this tumor. In
recent years attempts have been made to describe the use
of Gonadotrophin Releasing Hormone [GnRH] ana-
logues to induce a suppression of secretions and an apop-
tosis leading to a non-surgical cure [11], [12] &[13].
Pascale, Pugeat and Roberts suggested that androgen
secretion by ovarian virilizing tumor is gonadotrophin
dependent [11]. They concluded that various ovarian
androgen secreting tumors are not autonomous but
apparently depend on continuous gonadotrophin stimu-
lation.
Imai A, Lida K, Tamaya T suggested the various relation-
ships between GnRH receptor and tumor growth.
Increased Fas ligand level within GnRH receptor-bearing
tumors might promote apoptotic cell death through an
attack on intra-tumoral Fas positive cells that could, at
least in part, account for the anti-proliferative action of
the hormone [12]. The coupling of GnRH receptor to the
Gi protein subfamily may be a signaling pathway by
which GnRH acts in peripheral tumor [12].
So far these approaches have been tried primarily in non-
operable cases or recurrent disease. Therefore, at best,
these treatments can be considered experimental in the
present times. Further insight into the nature, biology and
behavior of these tumors may change the gold standard of
treatment from surgical extirpation to medical manage-
ment over time.
Conclusion
Ovarian steroid cell tumors, grouped under sex-chord
stromal tumors, account for less than 0.1% of all ovarian
tumors. They are usually benign, unilateral and are char-
acterized by a steroid cell proliferation [1] &[3]. These
tumors present with long history of often many years of
androgenic changes with variable frequency[1], [3], [4]
&[5]. This case is unique because of its acute presentation
over a four month period. The primary treatment is surgi-
cal extirpation of the primary lesion, and there are no
reports of effective treatment with radiation or chemo-
therapy [10]. In a young patient with stage IA disease, a
unilateral salpingo-ophorectomy is adequate since the fre-
quency of bilateralism is only 6% [1], [2] &[10].
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